Aurinia Pharmaceuticals Company Profile (NASDAQ:AUPH)

Aurinia Pharmaceuticals trades on the NASDAQ under the ticker symbol "AUPH."

Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) announced its quarterly earnings results on Monday, May, 15th. The company reported ($0.20) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.12) by $0.08. The company had revenue of $0.03 million for the quarter, compared to the consensus estimate of $0.05 million. Aurinia Pharmaceuticals had a negative net margin of 48,278.23% and a negative return on equity of 50.53%. View Aurinia Pharmaceuticals' Earnings History.

7 brokerages have issued twelve-month price targets for Aurinia Pharmaceuticals' stock. Their forecasts range from $8.00 to $14.00. On average, they anticipate Aurinia Pharmaceuticals' share price to reach $10.67 in the next year. View Analyst Ratings for Aurinia Pharmaceuticals.

Here are some recent quotes from research analysts about Aurinia Pharmaceuticals stock:

• 1. According to Zacks Investment Research, "Aurinia Pharmaceuticals Inc. is a late stage biopharmaceutical company. It focuses on the development of therapeutic immunomodulating drug candidate. The company's lead drug includes Voclosporin for the treatment of lupus nephritis. Aurinia Pharmaceuticals Inc. is headquartered in Victoria, Canada. " (6/27/2017)
• 2. FBR & Co analysts commented, "We increase our price target 22% from $9 to $11, as we think that with a balance sheet bolstered by a public offering that we estimate raised up to $161M in net proceeds, AUPH is now in a strong position to independently advance voclosporin (VCS), its investigational therapy for patients with active lupus nephritis (LN), into Phase III testing. As VCS is directed to an autoimmune disease that has been targeted by major pharmaceutical companies (Big Pharma) hungry for the next multi-billiondollar drug (FBR projects VCS could achieve >$2B in annual peak sales), we look for AUPH to receive an acquisition bid from a Big Pharma company in the next six to nine months, with an initial bid of $10 per share reasonable. We think AUPH is more likely to look to sign a partnership agreement; therefore, we look for a deal worth $500M to $700M in up-front and milestone payments to AUPH. We reiterate our Outperform rating." (3/22/2017)

Some companies that are related to Aurinia Pharmaceuticals include Insmed (INSM), Forward Pharma A/S (FWP), Omeros Corporation (OMER), Acorda Therapeutics (ACOR), Aduro Biotech (ADRO), Synergy Pharmaceuticals (SGYP), Ascendis Pharma A/S (ASND), Achaogen (AKAO), PTC Therapeutics (PTCT), NeuroDerm (NDRM), ZIOPHARM Oncology (ZIOP), Insys Therapeutics (INSY), Five Prime Therapeutics (FPRX), Keryx Biopharmaceuticals (KERX), Epizyme (EPZM), Aclaris Therapeutics (ACRS), Flexion Therapeutics (FLXN) and Retrophin (RTRX).

Aurinia Pharmaceuticals' management team includes the folowing people:

• Richard M. Glickman LL.D., Executive Chairman of the Board, Chief Executive Officer
• Dennis Bourgeault, Chief Financial Officer, Corporate Secretary
• Michael R. Martin, Chief Operating Officer
• Neil Solomons M.D., Chief Marketing Officer
• Celia Economides, Associate Vice President, Corporate Communications & Patient Advocacy
• Robert B. Huizinga, Vice President - Clinical Affairs
• Lawrence D. Mandt, Vice President - Regulatory and Quality
• George M. Milne Jr., Ph.D., Director
• Lorin Jeffry Randall, Director
• Benjamin Rovinski Ph.D., Independent Director

Aurinia Pharmaceuticals' stock is owned by a number of of institutional and retail investors. Top institutional investors include OTA Financial Group L.P. (0.21%), Creative Planning (0.20%) and State Treasurer State of Michigan (0.03%). View Institutional Ownership Trends for Aurinia Pharmaceuticals.

Aurinia Pharmaceuticals' stock was sold by a variety of institutional investors in the last quarter, including State Treasurer State of Michigan. View Insider Buying and Selling for Aurinia Pharmaceuticals.

Aurinia Pharmaceuticals' stock was acquired by a variety of institutional investors in the last quarter, including Creative Planning. View Insider Buying and Selling for Aurinia Pharmaceuticals.

Shares of Aurinia Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of Aurinia Pharmaceuticals stock can currently be purchased for approximately $6.51.